Welcome to our dedicated page for KIORA PHARMACEUTICALS news (Ticker: KPRX), a resource for investors and traders seeking the latest updates and insights on KIORA PHARMACEUTICALS stock.
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) is a clinical-stage biotechnology company developing small-molecule therapies for retinal disease. The KPRX news feed highlights company announcements on its development pipeline, clinical trial progress, strategic partnerships, and intellectual property related to its lead programs KIO-301 and KIO-104.
Recent news releases describe ongoing Phase 2 clinical trials for retinal diseases. The ABACUS-2 trial evaluates KIO-301, a molecular photoswitch being developed for vision restoration in patients with retinitis pigmentosa, with plans to expand into choroideremia and Stargardt disease. The KLARITY study investigates KIO-104, a non-steroidal, immuno-modulatory DHODH inhibitor, in patients with retinal inflammation and macular edema across several inflammatory retinal diseases, including posterior non-infectious uveitis and diabetic macular edema.
Investors following KPRX news can review quarterly financial updates, as Kiora reports research and development spending, collaboration credits, and cash position alongside clinical development updates. Press releases also cover collaboration agreements, such as the exclusive co-development and commercialization relationship with Théa Open Innovation for KIO-301 outside Asia and the option agreement with Senju Pharmaceutical for key Asian markets.
The news stream further includes information on new U.S. patents that expand protection for KIO-104 and the KIO-100 family of compounds, as well as Kiora’s participation in initiatives like the RARE-X Vision Consortium for rare ocular disorders. For those tracking the KPRX stock and the company’s retinal disease programs, this page aggregates Kiora’s official news, conference participation announcements, and other disclosures in one place.
Kiora Pharmaceuticals (NASDAQ: KPRX) has commenced a groundbreaking Phase 1 clinical trial for KIO-301 in Melbourne, Australia, targeting Retinitis Pigmentosa (RP), a rare inherited eye disease affecting approximately 1.5 million people worldwide. The trial aims to assess the safety and tolerability of KIO-301, a molecular photoswitch designed to restore vision in RP patients. Initial results will evaluate improvements in vision and brain activity related to image processing. The collaboration involves Kiora, Accelagen, and The Royal Adelaide Hospital, aiming to establish proof-of-concept that could lead to further studies.
Kiora Pharmaceuticals (NASDAQ: KPRX) reported its Q3 2021 financial results and provided updates on its corporate activities. The company has sharpened its pipeline strategy, focusing on KIO-301, a treatment for rare diseases. Key milestones include the initiation of multiple clinical trials in 2022 and the completion of various developmental studies. Financially, Kiora raised $10.75 million in August and reported $11.1 million in cash as of September 30, 2021, indicating a significant increase from the previous year. R&D expenses rose to $1.63 million, reflecting ongoing development efforts.
Kiora Pharmaceuticals, formerly EyeGate Pharmaceuticals, has rebranded to reflect its focus on developing innovative ophthalmic therapies, including a groundbreaking treatment for Retinitis Pigmentosa. The company’s pipeline includes three key assets: KIO-101, KIO-301, and KIO-201, each targeting various eye diseases. Upcoming milestones include Phase 1b trial initiation for KIO-301 in late-stage Retinitis Pigmentosa and a pre-IND meeting with the FDA regarding KIO-201. Kiora’s strategy aims to drive value through expanded clinical development efforts.